Mechanisms of mutations in myeloproliferative neoplasms.

Abstract excerpt

In recent years, a series of studies have provided genetic insight into the pathogenesis of myeloproliferative neoplasms (MPNs). It is now known that JAK2V617F mutations are present in 90% of patients with polycythaemia vera (PV), 60% of patients with essential thrombocytosis (ET) and 50% of patients with myelofibrosis (MF). Despite the high prevalence of JAK2V617F mutations in these three myeloid malignancies,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK2 gene
• Share to TET2 gene
• Share to Janus Kinase 2